Allogene Therapeutics, Inc. provided earnings guidance for the full year 2019. For the year, the company continues to expect full-year 2019 net losses to be between $200 million and $210 million dollars, including estimated non-cash stock-based compensation expense of $45 million to $50 million and excluding any impact from potential business development activities.